[go: up one dir, main page]

WO2011117313A1 - Systèmes d'administration de médicaments à dissolution rapide - Google Patents

Systèmes d'administration de médicaments à dissolution rapide Download PDF

Info

Publication number
WO2011117313A1
WO2011117313A1 PCT/EP2011/054482 EP2011054482W WO2011117313A1 WO 2011117313 A1 WO2011117313 A1 WO 2011117313A1 EP 2011054482 W EP2011054482 W EP 2011054482W WO 2011117313 A1 WO2011117313 A1 WO 2011117313A1
Authority
WO
WIPO (PCT)
Prior art keywords
fast dissolving
oral
film according
dissolving film
difficulties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/054482
Other languages
English (en)
Inventor
Dominique Costantini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioalliance Pharma SA
Original Assignee
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10305288A external-priority patent/EP2377526A1/fr
Priority claimed from US12/729,735 external-priority patent/US20110237563A1/en
Priority to CN2011800230084A priority Critical patent/CN103025321A/zh
Priority to EP11709445A priority patent/EP2549988A1/fr
Priority to CA2794042A priority patent/CA2794042A1/fr
Priority to KR1020127026904A priority patent/KR20130012067A/ko
Application filed by Bioalliance Pharma SA filed Critical Bioalliance Pharma SA
Priority to BR112012024092A priority patent/BR112012024092A2/pt
Priority to RU2012144848/15A priority patent/RU2560693C2/ru
Priority to AU2011231645A priority patent/AU2011231645A1/en
Publication of WO2011117313A1 publication Critical patent/WO2011117313A1/fr
Anticipated expiration legal-status Critical
Priority to ZA2012/07900A priority patent/ZA201207900B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Definitions

  • the present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition, leading to difficulties in swallowing oral medicine forms and thus difficulties in treating said illnesses.
  • the present invention discloses the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with dysphagia and/or odynophagia and/or aspiration risk.
  • Another aspect of the present invention is the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for the treatment of dysphagia and/or odynophagia and/or aspiration risk.
  • dysphagia a general term meaning difficulty in swallowing, or more particularly "odynophagia”, meaning a painful swallowing or “aspiration risk”, when material such as medicine, food, saliva, or nasopharyngeal secretions are inhaled into the airway or respiratory tract instead of digestive tract.
  • Dysphagia or difficulty in swallowing, is a condition or symptom, which can be caused by many different conditions, injuries or diseases.
  • Dysphagia can cause choking, aspiration of food or liquid into the lungs, which can lead to pneumonia (called “aspiration pneumonia") or incomplete administration of oral medication. These factors can at least discomfort a patient, but may also interfere with or complicate conventional treatment of patients when treating other coexisting disorders.
  • head injuries brain stem impairment, cerebral vascular accidents, Parkinsonism, Alzheimer's disease, muscular dystrophy, cerebral palsy, cancer (notably brain tumors), diabetes, medication side effects, advanced HIV infections, gastrointestinal disorders, gastro esophageal or reflux disorder.
  • dysphagia Patients with head/neck injuries or AIDS are also often concerned by dysphagia. Such conditions are often experienced by older patients. As the population ages, elderly people suffering from dysphagia are increasing. Many elderly people may have difficulty in swallowing foods and develop symptoms of dysphagia. In many cases, dysphagia may cause aspiration, and the entry of the aspirated substance into the lung may cause bacterial infection, resulting in pneumonia.
  • dysphagia is induced by drugs used in a long-term treatment to treat other disorder. It is the case, for example, for the nervous central system drugs, cardio-vascular drugs or anti-inflammatory and analgesic drugs.
  • children are at highest risk for death and injury from mechanical airway obstruction, due in large part to their immature anatomy (Tarrago, 2000). They do not have fully developed teeth for chewing, and lack molars. In addition, their airways are small, they have less chewing capacity, and their respiratory rate is high compared to older children and adults (Gregori, 2008). Therefore, aspiration is a real risk for children.
  • Dysphagia can often be improved thanks to hygiene and dietetic methods or bioactive agent such as proton pump inhibitors (PPI), anti-H2 or prokinetic agents.
  • PPI proton pump inhibitors
  • anti-H2 anti-H2
  • prokinetic agents include secondary effects (iatrogenic pathologies) and long-term usage must be avoided.
  • PPIs are very strong inhibitors of the acidic stomach secretion. They are particularly indicated in the treatment of erosive oesophagitis or peptic stenosis. They could also be used on a long term basis but they have strong iatrogenic effects and are also responsible for patient's confusion. For the elderly over 80, they should not be used too long. These are omegrazole, lanzopra-izole and pantoprazole.
  • Anti-H2 are efficient on 60% of the symptoms and efficiency decreases with time. These are cimetidine, ranitidine, famotidine or nizatidine. They also have strong iatrogenic effects, notably oligoptyalism and must be handled with precaution in patients who have a decrease of creatine clearance, which is more and more frequent with the increase in age.
  • Prokinetic agents are as effective as anti-H2s but have the same drawbacks and more side effects (diarrhea, nausea, medication interactions).
  • liquid form is more convenient to be swallowed than solid form.
  • handling and delivering said liquid system is always a challenge compared to solid system.
  • liquid dosage form often presents instability when stored and it is more difficult to precisely dose the bioactive agent when administered to patients. Therefore, dosage forms with the convenience of liquids and storage ability and dose precision of solid oral dosage form is desirable.
  • liquid form is still unsuitable to patient presenting severe difficulties to swallow.
  • tablets have been formulated to be quick dispersed in the mouth.
  • the bioactive agent thus rapidly dissolves in the saliva to provide a liquid formulation which is very easily swallowed.
  • the oral disintegration/dispersion time appears to be a critical feature to solve the drawback of the art. Indeed, oral disintegration/dispersion time of current disintegrating/dispersing tablet often take few minutes, which is too long to overcome a risk associated with choking or gagging that occurs with subjects having limited control of their swallowing reflexes.
  • Zophren (Zofran®) is a tablet which contains ondansetron as bioactive principle. Zophren is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Zophren is a highly specific and selective serotonin 5- HT3 receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors.
  • Sofran ODT® for Zofran Orally Disintegrating Tablets
  • Sofran ODT® for Zofran Orally Disintegrating Tablets
  • the summary of product characteristics of Zofran ODT® reports that in children less than 6 years of age, due to the risk of aspiration with the tablet, dissolution with water or syrup prior to swallowing should be recommended. Therefore, Zofran® and Zofran ODT® are not completely suitable in case of dysphagia and risk aspiration.
  • the films have an adhesive layer and a non-adhesive backing layer and are intended to adhere to the mucosal surface.
  • Biegajski et al. U.S. Patent No. 5,700,478, describes a water-soluble pressure-sensitive mucoadhesive suitable for use in a mucosal-lined body cavity.
  • the purported advantage of these mucoadhesive films resides in their transmucosal route of absorption and thus their ability to bypass the gastrointestinal tract, and barriers in the gastrointestinal tract to drug absorption such as first pass metabolism and decomposition of the active ingredient in the stomach.
  • a delivery system targets a new route of administration and therefore cannot be use for bioactive agents for which their clinical efficacy has been proven for oral administration.
  • the present invention relates to film dosage forms that are formulated or administered for gastrointestinal absorption of the bioactive agent, and that are bioequivalent to and interchangeable with existing orally administered drug products.
  • These film dosage forms are non-mucoadhesive; and they are absorbed predominantly through the gastrointestinal tract.
  • these dosage forms are specially formulated to meet exacting bioavailability requirements, or to be bioequivalent to existing orally administered dosage forms and which is particularly suitable for patients with dysphagia as they quickly disintegrate in the mouth when exposed to saliva, and does not need added water to accelerate its disintegration.
  • the present invention provides an oral fast dissolving film comprising an active principle for treating illnesses of patients with critical buccal condition. Added water being not required to facilitate the dissolution or swallowing of the active principle.
  • critical buccal condition is dysphagia, aspiration risk, odynophagia, chemotherapy and/or radiotherapy-induced mucositis, head and neck or oesophageal cancer, or reduced salivary flow.
  • a further preferred object of the invention is an oral fast dissolving film comprising an active principle for treating illnesses such as, neuropathy diseases (Alzheimer diseases, Parkison diseases, epilepsy, ...) or lung diseases.
  • a more preferred object of the invention is an oral fast dissolving film comprising an active principle for treating illnesses of children or elderly.
  • Patient with iatrogenic pathologies are also preferred. As usually in geriatrics, iatrogenic pathologies are often implicated.
  • Some drugs may for instance induce salivary secretion impairments (antidepressants, tricyclics, anticholinergics%), even alterations of the oropharyngeal sensation (toxins).
  • the oral fast dissolving film of the invention is also suitable to treat a patient with one or more of the following bioactive principle, which could induce oligoptyalism in long-term treatment: Drugs for the nervous central system
  • Benzodiazepines alprazolam (Xanax ® ), bromazepam (Lexomil ® ), Clorazepate (Tranxene ® ), lorazepam (Temesta ® ),
  • Imipraminics clomipramine ((Anafranil ® ), imipramine (Tofranil ® ), amiptriptlyline (Laroxyl ® ), trimipramine (Surmontil ® ), maprotiline (Ludiomil ® )
  • Serotoninergics fluvoxamine (Floxyfral ® ), fluoxetine (Prozac ® ), paroxetine (Deroxatn, sertraline (Zoloft ® ), citolopram
  • Phenothiazines chlorpromazine (Largactil ® ), levome romazine (Nozinan ® ), cyamemazine (Tercian ® ), thioridazine (Mellerr), propericiazine (Neuleptil ® ), thiopreperazine (Majeptil ), pipotiazine (piportil ® )
  • Butyrophenones haloperidol (Haldol ® ), droperidol (Droleptan ® ), pimozine (Orap ® ), pipamperone (Dipiperon ® )
  • Antiarythmics disopyramide ( Rythmodan ® , Isotythm LP), flecabide (Flecai ' ne ® )
  • Alpha-1 blockers urapidil (Eupressyl ® , Mediatensyl ® ), prazosine (Minipress ® , AlpressLP)
  • Betablockers acebutolol (Acebutol ® , Sectral ® ), atenolol (Atenolol ® , Tenormine ® , Betatop ® ), betaxolol (Kerlone ® ),
  • Bradycardising diltiazem (Tildien ® , Bi-Tildiem ® , Dilt azel ® , Mono-Tildiem ® , Cardiosta LP), bepridil (Unicordium ® ), verapamil (verapramil LP, Isoptine LP)
  • Dihydropyridines Dihydropyridines: amiodipine (Amlor ® ), felodipine (Flodil LP), isradipine (Icaz LP), nicardipine (Loxen LP), nitrendipine (Baypress ® . NifreV), nifedipine (Nifedipine LP, Adalate LP, Chronadalate LP)
  • morphin Major: morphin (Morphine LP. Moscontin LP, Skenan LP, Kapanol LP), buprenorphin (Temgesic ® ), nalbuphine (Nubain ® ).
  • codein Efferalgan ® Codein Efferalgan ® , Codein Dafalgan ® , Lindilane ® , Codoliprane
  • dihydrocodeine Dicodin LP
  • Antihistaminics mequitazine (Primatan ® ), cetirizine (Virlix ® , Zyrtec ® ), ioratidine (Clarityne ® ), promethazine (Phenergan ® ), alimethazine (Theralene ® ), dexchlorpheniramine (Polaramine Repetabs, Polaramine), oxatomide (Zaditen LP)
  • Non musculotropic tiemobium (Visceralgine ® ), dihexyver ne (Spasmodex ® ) Musculotropic: alverine (Spasmaverine ® , Meteospasmyl ® )
  • Bronchodilatators salbutamol (Ventoline ® ), terbutalin (Bricanyl ® ), pirtuberol (Maxair ® ), formoterol (Foradil ® ),
  • Urology (Alpha-I-Blockers): alfuzosine (Xantal LP, Urion ® ). tamsulosine (Josir LP, OmixLP)
  • Anti-ulcerous sucrafalte (Keal ® , Ulcar ® ), lansoprazole (Lanzor ® , Ogast ® ), omeprazole (Mopral ® , Zoltum ® ), famotidine (Pepdine ® )
  • Anti-cancerous busufan (Myleran ® ), procarbazine (Natulan ® )
  • griseofuline (Fulcine Forte, Grisefuline ® ), flucytosine (Ancotil ® ), metronidazole (Flagyl ® ), pyrimethamine
  • Another object of the present invention is to provide an oral fast dissolving film comprising an active principle for the treatment of dysphagia, aspiration risk, odynophagia, chemotherapy and/or radiotherapy-induced mucositis, head and neck or oesophageal cancer, or reduced salivary flow.
  • the bioactive agent to treat the dysphagia is proton pump inhibitors (PPI), anti-H2 or prokinetic agents.
  • the bioactive agent is suitable to treat illnesses despite its adverse effect to induce dysphagia with long-term treatment.
  • the oral fast dissolving film of the invention comprises an bioactive agent, a hydrophilic binder and a water-soluble diluents.
  • the bioactive agent is selected from: donepezil hydrochloride; ondansetron, ondansetron base; desloratadine; olanzapine; risperidone; rivastigmine tartrate; sildenafil; vardenafil; galantamine; diclofenac potassium; buprenorphine HCI; naloxone HC1 dehydrate; alprazolam; clonazepam; diazepam; lorazepam; sumatriptan; eletriptan; rizatriptan; zolmitriptan; naratriptan; almotriptan; frovatriptan; cetirizine hydrochloride; loratadine; ambroxol hydrochloride; apomorphine; ascorbic acid; betamethasone; caffeine; dextromethorphan; glimepiride; hydrocortisone; ketotifen; loperamide; meclo
  • a particularly preferred bioactive agent of the present invention is ondansetron and more preferably ondansetron base. Furthermore, the oral fast dissolving film of the invention comprises from 0.05% to 50% by weight of said bioactive agent.
  • the oral fast dissolving film of the invention also comprises from 40% to 80% by weight of one or more ingredients that constitute a hydrophilic binder and a water soluble diluent
  • the hydrophilic binder can preferably be Polyvinylalcohol
  • the water-soluble diluents can preferably be rice starch.
  • the invention provides a non-mucoadhesive orally disintegrating film, able to disintegrate upon contact with saliva in the buccal cavity within about sixty seconds, comprising ondansetron base, in combination with a hydrophilic binder and a water-soluble diluent, and means for promoting gastrointestinal absorption of said ondansetron, wherein: (a) said means for promoting gastrointestinal absorption comprises ondansetron in base form; (b) said film comprises from about 4 to about 24 mg of ondansetron base; (c) ondansetron base is present in an amount from about 0.05% to about 50% (w/w), based on the total weight of the formulation, (d) said film has a Tmax of from about 1 .5 to about 2.5 hours, and (e) said ondansetron base has an absolute bioavailability in said dosage form of from about 45% to about 75%.
  • the film most preferably contains 4 or 8 mg of ondansetron base.
  • disintegrate has its usual and customary meaning in the pharmaceutical arts, as described in ⁇ 701 > of the U.S. Pharmacopoeia (2005 USP/NF) for uncoated tablets, using a basket rack assembly operating at 30 cycles per minute through a distance of 5.5 cm, in a disintegration medium at 37°C.
  • disintegration requirements are discussed herein, they are preferably met under the foregoing testing conditions, at a pH of 4.0 or 6.8.
  • a film or other dosage form is said to be "disintegrated” if it is completely disintegrated, a state in which any residue of the unit remaining on the screen of the test apparatus, or in the mouth, is a soft mass having no palpably film core, or fragments of a tablet coating or capsule shell. Disintegration thus does not imply complete dissolution of the dosage unit or even the active constituent, although a dissolved dosage unit would typically be completely disintegrated.
  • disintegration thus does not imply complete dissolution of the dosage unit or even the active constituent, although a dissolved dosage unit would typically be completely disintegrated.
  • dissolution also has its usual and customary meaning in the pharmaceutical arts, as described in ⁇ 71 1 > and ⁇ 724> of the U.S. Pharmacopoeia (2005 USP/NF). Therefore, a film is said to be "dissolved” if, upon testing by the method of U.S. Pharmacopoeia (2005 USP/NF), the amount of active agent dissolved in the dissolution medium exceeds a predetermined percentage.
  • a “orally dissolving or orally dispersible tablet” refers to an uncoated tablet intended to be placed in the mouth where it can disperse rapidly before being swallowed, as described in Eur. Ph. 5.0. An ODT disintegrates within three minutes when tested according to the disintegration testing described herein.
  • non-mucoadhesive means that the dosage form is not designed for administration of the active pharmaceutical agent through the oral mucosa. I.e. the dosage form is not designed to adhere to the mucosal surfaces of the buccal cavity as an intact film or disintegrated film residue.
  • absolute bioavailability refers to the availability of the active drug in systemic circulation after non-intravenous administration (i.e., after oral, rectal, transdermal, subcutaneous administration).
  • a pharmacokinetic study must be done to obtain a plasma drug concentration versus time plot for the drug after both intravenous (IV) and non-intravenous administration.
  • the absolute bioavailability is the dose-corrected area under curve (AUC) non-intravenous divided by AUC intravenous.
  • pharmacokinetic parameters i.e. T max, absolute bioavailability, etc.
  • T max absolute bioavailability
  • wt. % as used herein with reference to the final product (i.e., the film, as opposed to the formulation used to create it), denotes the percentage of the total dry weight contributed by the subject ingredient. This theoretical value can differ from the experimental value, because in practice, the film typically retains some of the water and/or ethanol used in preparation.
  • the calculated dose is based on the molecular weight of the active pharmaceutical ingredient, which includes the cationic and anionic species in the case of a salt, and just the base when the active principle is not present as a salt.
  • the salt of a drug and pharmaceutically acceptable salts thereof it will be understood that salts of the base form of the base drug are intended.
  • Chronic buccal conditions means a patient with a dysphagia, odynophagia, aspiration risk oropharyngeal candidiasis, herpes, mucositis, severe aphteous and/or lichen planus
  • Fast dissolving or “flash dissolving” means a dissolving within less than 60 seconds and more preferably within less than 30 seconds.
  • the present invention provides a physiologically acceptable film that is particularly well adapted to disintegrate rapidly when placed on the tongue of a patient, and to facilitate gastrointestinal absorption of the pharmaceutically active agent.
  • the film and bioactive agent need not dissolve entirely in the mouth. The film could be not entirely dissolved.
  • the film may be characterized by the time it takes to disintegrate completely, and it preferably disintegrates to a soft residue within about 10, 20, 30 or 60 seconds of administration, after which it is swallowed. These disintegration times are preferably observed in the oral cavity when the film is administered, as well as when tested for disintegration using the method described in Ph. Eur. 2.9.1 .
  • the prompt disintegration and swallowing of the film helps to assure gastrointestinal absorption of the dosage form.
  • the film is not of the conventional mucoadhesive type, designed to deliver active agent transmucosally.
  • Preferred films according to the invention comprise a pharmaceutically active agent, a film- forming agent, and at least one of the following additional ingredients: water, antimicrobial agents, water soluble diluents such as plasticizing agents, softeners, and fillers, flavoring agents, saliva stimulating agents, cooling agents, stabilizers, surfactants, stabilizing agents, emulsifying agents, thickening agents, binding agents, coloring agents, sweeteners, fragrances, triglycerides, preservatives, polyethylene oxides, propylene glycol, and the like.
  • water antimicrobial agents
  • water soluble diluents such as plasticizing agents, softeners, and fillers
  • flavoring agents such as plasticizing agents, softeners, and fillers
  • saliva stimulating agents saliva stimulating agents
  • cooling agents stabilizers
  • surfactants stabilizing agents
  • stabilizing agents emulsifying agents
  • thickening agents binding agents
  • coloring agents coloring agents
  • sweeteners fragrances
  • triglycerides preservatives
  • the film comprises one or more ingredients that act both as water soluble binding agents and hydrophilic polymers, such as polyvinyl alcohol, polyethylene glycol (“PEG”), propylene glycol, polyethylene oxide, and starches, celluloses, gelatines and the like. Therefore, when it is stated herein that a formulation comprises a water soluble binding agent and a hydrophilic polymer, it will be understood that these two agents may be describing one solitary ingredient.
  • the finished film product preferably comprises from about 40 to about 80 wt.% of these ingredients, and more preferably from about 50 to about 75 wt.%.
  • the active agent preferably makes up from 5 to 20 wt.% of the finished film formulation, more preferably from about 8 to about 15 wt.%.
  • the formulation is also preferably "surfactant free.” Alternatively, the formulation may contain one or more surfactants.
  • a preferred taste masking agent which facilitates the dissolution of the product, and it is believed helps to maintain the amorphous state of certain active ingredients such as donepezil, is an aminoalkyl methacrylate copolymer such as that marketed as Eudragit E PO.
  • the aminoalkyl methacrylate copolymer preferably contains diethyaminoethyl residues, and preferably comprises from about 20 to about 26 wt.% of such groups in a dry substance basis.
  • the average molecular weight of the copolymer preferably ranges from about 120,000 to about 180,000, or from about 140,000 to about 160,000, most preferably about 150,000.
  • Preferred methacrylic monomers include butyl methacrylate and methyl methacrylate.
  • This agent is preferably present in the final film in an amount of from about 5 to about 25 wt.%, preferably from about 10 to about 20 wt.%, and more preferably from about 12 to about 18 wt.%.
  • the copolymer is preferably micronized to an average particle size less than 100, 100, or 10 microns.
  • Another taste masking agent is a cyclodextrin or derivative thereof. This component is preferably present in the final film in an amount of from about 10 to about 50 wt.% or, in alternative embodiments, from about 10 to about 40 wt.%, or from about 20 to about 35 wt.%.
  • a preferred stabilizer, especially for donepezil films, is citric acid, especially anhydrous citric acid, and in a preferred embodiment the final product comprises from about 0.5 to about 2.0 wt.% citric acid, or from about 0.75 to about 1 .25 wt.% citric acid.
  • the formulation may contain one or more surfactants.
  • Ondansetron is chemically known as ( ⁇ ) 1 ,2,3,9 tetrahydro-9-methyl-3-[(2-methyl-IH- imidazol-l-yl)methyl]-4H-carbazol-4-one, and its base is represented by the following chemical structure:
  • the invention provides an ondansetron film strip, wherein the ondansetron is preferably provided in base form to promote Gl absorption of the ondansetron.
  • the invention also provides a non-mucoadhesive orally disintegrating film, able to disintegrate upon contact with saliva in the buccal cavity within about sixty seconds, comprising ( ⁇ ) 1 ,2,3,9 tetrahydro-9-methyl-3-[(2-methyl-IH-imidazol-l-yl)methyl]-4H- carbazol- 4-one (ondansetron), in combination with a hydrophilic binder and a water-soluble
  • said means for promoting gastrointestinal absorption comprises ondansetron in base form;
  • said film comprises from about 4 to about 24 mg of ondansetron base;
  • ondansetron base is present in an amount from about 0.05% to about 50% (w/w), based on the total weight of the formulation,
  • said film has a T max of from about 1 .5 to about 2.5 hours, and
  • said ondansetron base has an absolute bioavailability in said dosage form of from about 45% to about 75%.
  • the film most preferably contains 4 or 8 mg of ondansetron base, and is preferably formulated according to the general formulation techniques described in this document.
  • ondansetron can exist in several polymorphic forms, including Forms A, B, C, D and E. See WO 03/093260 and WO 2005/080381 . It has been unexpectedly found that the crystalline purity of the ondansetron in the final product influences the physical properties of the final film, and that highly pure form B is particularly preferred. In particular, for films stored at higher temperatures 60 ' ⁇ ).
  • the film comprises form B polymorph that is essentially free of other polymorphic forms, i.e. greater than 70, 80, 90, 95, 98 or even 99% pure.
  • Form B can be evaluated by X-ray diffraction.
  • the product is characterized by a melting endotherm at 244 ⁇ 2 q C when subjected to differential scanning calorimetry.
  • the invention provides methods of using the ondansetron film strips of the present invention, for the treatment or prevention of emesis, including emesis resulting from postoperative nausea and vomiting, chemotherapy induced nausea and vomiting, and radiation induced nausea and vomiting. Therefore, the invention also provides a method of treating or preventing emesis in a human patient comprising administering to the tongue of said patient, preferably from one to three times daily, an ondansetron film strip of the present invention that contains from about 4 to about 24 mg of ondansetron base, preferably 4 or 8 mg of ondansetron base. The method is preferably practiced with an additional step that promotes gastrointestinal absorption of said ondansetron, such as swallowing said film within about sixty seconds of said administration, with or without water.
  • Example 1 Representative Ondansetron Formulation
  • Table 1 depicts a representative film formulation that contains 8.0 mg of ondansetron as its base, in order to promote gastrointestinal absorption.
  • Example 2 Zophren (Zofran®) side effects report dysphagia
  • Zofran® tablette
  • Zofran ODT® Oro Dispersible Tablet
  • Example 3 Comparison between Ondansetron ODT (Zofran OPT®) and film of the invention containing ondansetron In a salivary media, as defined in WO2008/025926, and in application of a disintegration test we compared the time needed for dissolution of Zofran ODT® and the film of the invention.
  • Zofran ODT® requires between 2 and 3 minutes to dissolves, while the film of the invention containing ondansetron needs less than 60 seconds to dissolve.
  • Example 4 Preference study between three galenic formulations of ondansetron (Zofran®, Zofran ODT® and film of the invention containing ondansetron) for preventing and/or treating radiotherapy or chemotherapy induced-nausea or vomiting in patients with difficulties for swallowing.
  • ondansetron Zofran®, Zofran ODT® and film of the invention containing ondansetron

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'administration d'agents bioactifs par l'intermédiaire de systèmes d'administration par voie orale de médicaments à dispersion/dissolution rapide pour le traitement de maladies de patients ayant un état buccal critique conduisant à des difficultés pour avaler des formes médicamenteuses orales et donc à des difficultés pour traiter lesdites maladies. En particulier, la présente invention porte sur l'administration d'agents bioactifs par l'intermédiaire de systèmes d'administration par voie orale de médicaments à dispersion/dissolution rapide pour le traitement de maladies de patients présentant une dysphagie et/ou une odynophagie et/ou un risque d'aspiration. Un autre aspect de la présente invention porte sur l'administration d'agents bioactifs par l'intermédiaire de systèmes d'administration par voie orale de médicaments à dispersion/dissolution rapide pour le traitement de la dysphagie et/ou de l'odynophagie et/ou du risque d'aspiration.
PCT/EP2011/054482 2010-03-23 2011-03-23 Systèmes d'administration de médicaments à dissolution rapide Ceased WO2011117313A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2011231645A AU2011231645A1 (en) 2010-03-23 2011-03-23 Fast dissolving drug delivery systems
RU2012144848/15A RU2560693C2 (ru) 2010-03-23 2011-03-23 Быстро растворяющиеся системы, освобождающие лекарственные препараты
EP11709445A EP2549988A1 (fr) 2010-03-23 2011-03-23 Systèmes d'administration de médicaments à dissolution rapide
CA2794042A CA2794042A1 (fr) 2010-03-23 2011-03-23 Systemes d'administration de medicaments a dissolution rapide
KR1020127026904A KR20130012067A (ko) 2010-03-23 2011-03-23 속용성 약물 전달 시스템
CN2011800230084A CN103025321A (zh) 2010-03-23 2011-03-23 快速溶解的药物释放系统
BR112012024092A BR112012024092A2 (pt) 2010-03-23 2011-03-23 filme de rápida dissolução oral
ZA2012/07900A ZA201207900B (en) 2010-03-23 2012-10-19 Fast dissolving drug delivery systems

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10305288A EP2377526A1 (fr) 2010-03-23 2010-03-23 Systèmes d'administration de médicaments à dissolution rapide
US12/729,735 2010-03-23
EP10305288.2 2010-03-23
US12/729,735 US20110237563A1 (en) 2010-03-23 2010-03-23 Fast dissolving drug delivery systems

Publications (1)

Publication Number Publication Date
WO2011117313A1 true WO2011117313A1 (fr) 2011-09-29

Family

ID=44070534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/054482 Ceased WO2011117313A1 (fr) 2010-03-23 2011-03-23 Systèmes d'administration de médicaments à dissolution rapide

Country Status (9)

Country Link
EP (1) EP2549988A1 (fr)
KR (1) KR20130012067A (fr)
CN (1) CN103025321A (fr)
AU (1) AU2011231645A1 (fr)
BR (1) BR112012024092A2 (fr)
CA (1) CA2794042A1 (fr)
RU (1) RU2560693C2 (fr)
WO (1) WO2011117313A1 (fr)
ZA (1) ZA201207900B (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102846581A (zh) * 2012-09-28 2013-01-02 天津市聚星康华医药科技有限公司 一种盐酸氨溴索口腔速溶膜及其制备方法
CN102860997A (zh) * 2012-09-28 2013-01-09 天津市聚星康华医药科技有限公司 一种遮味的昂丹司琼口腔速溶膜及其制备方法
CN102920683A (zh) * 2012-06-11 2013-02-13 江苏豪森药业股份有限公司 奥氮平口腔速溶膜
JP2015533155A (ja) * 2012-10-11 2015-11-19 アイエックス バイオファーマ リミテッド 固体剤形
CN108078962A (zh) * 2018-01-29 2018-05-29 中国药科大学 一种盐酸多奈哌齐口腔速溶膜剂及其制备方法
US11179331B1 (en) 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate
US11975097B2 (en) 2009-10-30 2024-05-07 Ix Biopharma Ltd. Fast dissolving solid dosage form
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103432105A (zh) * 2013-09-02 2013-12-11 天津市聚星康华医药科技有限公司 一种美克洛嗪口腔用膜剂及其制备方法
CN104666280B (zh) * 2015-03-21 2017-10-13 合肥华方医药科技有限公司 一种格列吡嗪口腔速溶膜及其制备方法
CN104958279A (zh) * 2015-06-27 2015-10-07 万特制药(海南)有限公司 氯雷他定口腔速溶膜及其制备方法
CN104940174A (zh) * 2015-07-23 2015-09-30 合肥华方医药科技有限公司 一种盐酸多奈哌齐口腔速溶膜剂的制备方法
DE102017112527B4 (de) * 2017-06-07 2019-01-03 Lts Lohmann Therapie-Systeme Ag Schnell zerfallende Schaumwafer mit hohem Flächengewicht
CA3087272A1 (fr) * 2017-12-29 2019-07-04 Laxxon Medical Ag Systeme d'administration de medicament
CN108142940B (zh) * 2018-02-05 2021-05-14 中山大学附属第三医院（中山大学肝脏病医院） 一种促吞咽软片及其制备方法
CA3106579A1 (fr) * 2018-07-15 2020-01-23 Rapid Dose Therapeutics Corp. Bande de film cannabinoide dispersible par voie orale
CN118082156A (zh) 2019-01-31 2024-05-28 日精Asb机械株式会社 预制件的温度调节装置和温度调节方法以及树脂成型容器的制造装置和制造方法
CN117863519A (zh) 2019-01-31 2024-04-12 日精Asb机械株式会社 树脂容器制造设备、温度调节装置、树脂容器制造方法及温度调节方法
KR102646476B1 (ko) 2019-01-31 2024-03-11 닛세이 에이. 에스. 비 기카이 가부시키가이샤 수지제 용기의 제조장치 및 제조방법
EP3919254A4 (fr) 2019-01-31 2022-10-12 Nissei Asb Machine Co., Ltd. Dispositif de production et procédé de production pour contenants en résine

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700478A (en) 1993-08-19 1997-12-23 Cygnus, Inc. Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
WO2003093260A1 (fr) 2002-04-30 2003-11-13 Biogal Gyogyszergyar Rt. Nouvelles formes cristallines d'ondansetron, procedes de preparation correspondant, compositions pharmaceutiques contenant ces nouvelles formes et procedes de traitement de la nausee au moyen des ces nouvelles formes
US6750291B2 (en) 2002-04-12 2004-06-15 Pacific Corporation Film-forming agent for drug delivery and preparation for percutaneous administration containing the same
WO2005080381A1 (fr) 2004-01-21 2005-09-01 Inke, S.A. Nouvelles formes polymorphes d'ondansetron et leurs procedes de preparation, et compositions pharmaceutiques contenant lesdites nouvelles formes polymorphes et leur utilisation comme antivomitif
WO2008025926A2 (fr) 2006-09-01 2008-03-06 Unither Developpement Substitut salivaire
WO2008040534A2 (fr) 2006-10-02 2008-04-10 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Formes pharmaceutiques à base de film non muco-adhésif
WO2008098195A2 (fr) * 2007-02-09 2008-08-14 Todd Maibach Film comprenant de la nitroglycérine
WO2008140460A1 (fr) * 2007-05-16 2008-11-20 Fmc Corporation Forme solide
US20090004254A1 (en) * 2007-06-19 2009-01-01 Todd Maibach Film comprising active drugs
US20090047350A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Perforated water soluble polymer based edible films
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
WO2009043588A2 (fr) * 2007-10-02 2009-04-09 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Films antibactériens de régulation de ph pour la cavité buccale ou vaginale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063927A2 (fr) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions et procedes permettant de traiter les troubles gastro-intestinaux
PL1648421T3 (pl) * 2003-07-24 2018-03-30 Glaxosmithkline Llc Folie rozpuszczające się w jamie ustnej
ATE426399T1 (de) * 2004-02-23 2009-04-15 Euro Celtique Sa Missbrauchsichere transdermale abgabevorrichtung fur opioide, enthaltend opioidantagonist in form von mikrokugelchen
DE102005033942A1 (de) * 2005-07-20 2007-02-22 Hexal Ag Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für Antiemetikum oder Antimigränemittel

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700478A (en) 1993-08-19 1997-12-23 Cygnus, Inc. Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6750291B2 (en) 2002-04-12 2004-06-15 Pacific Corporation Film-forming agent for drug delivery and preparation for percutaneous administration containing the same
WO2003093260A1 (fr) 2002-04-30 2003-11-13 Biogal Gyogyszergyar Rt. Nouvelles formes cristallines d'ondansetron, procedes de preparation correspondant, compositions pharmaceutiques contenant ces nouvelles formes et procedes de traitement de la nausee au moyen des ces nouvelles formes
WO2005080381A1 (fr) 2004-01-21 2005-09-01 Inke, S.A. Nouvelles formes polymorphes d'ondansetron et leurs procedes de preparation, et compositions pharmaceutiques contenant lesdites nouvelles formes polymorphes et leur utilisation comme antivomitif
WO2008025926A2 (fr) 2006-09-01 2008-03-06 Unither Developpement Substitut salivaire
WO2008040534A2 (fr) 2006-10-02 2008-04-10 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Formes pharmaceutiques à base de film non muco-adhésif
WO2008098195A2 (fr) * 2007-02-09 2008-08-14 Todd Maibach Film comprenant de la nitroglycérine
WO2008140460A1 (fr) * 2007-05-16 2008-11-20 Fmc Corporation Forme solide
US20090004254A1 (en) * 2007-06-19 2009-01-01 Todd Maibach Film comprising active drugs
US20090047350A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Perforated water soluble polymer based edible films
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
WO2009043588A2 (fr) * 2007-10-02 2009-04-09 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Films antibactériens de régulation de ph pour la cavité buccale ou vaginale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2549988A1 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11975097B2 (en) 2009-10-30 2024-05-07 Ix Biopharma Ltd. Fast dissolving solid dosage form
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
CN102920683A (zh) * 2012-06-11 2013-02-13 江苏豪森药业股份有限公司 奥氮平口腔速溶膜
CN102920683B (zh) * 2012-06-11 2013-08-14 江苏豪森药业股份有限公司 奥氮平口腔速溶膜
WO2013185505A1 (fr) * 2012-06-11 2013-12-19 江苏豪森药业股份有限公司 Membrane instantanée orale à l'olanzapine
CN102846581A (zh) * 2012-09-28 2013-01-02 天津市聚星康华医药科技有限公司 一种盐酸氨溴索口腔速溶膜及其制备方法
CN102860997A (zh) * 2012-09-28 2013-01-09 天津市聚星康华医药科技有限公司 一种遮味的昂丹司琼口腔速溶膜及其制备方法
JP2015533155A (ja) * 2012-10-11 2015-11-19 アイエックス バイオファーマ リミテッド 固体剤形
EP2906201A4 (fr) * 2012-10-11 2016-10-19 Ix Biopharma Ltd Forme de dosage solide
CN108078962A (zh) * 2018-01-29 2018-05-29 中国药科大学 一种盐酸多奈哌齐口腔速溶膜剂及其制备方法
US11179331B1 (en) 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate

Also Published As

Publication number Publication date
CN103025321A (zh) 2013-04-03
AU2011231645A2 (en) 2012-12-20
RU2012144848A (ru) 2014-04-27
BR112012024092A2 (pt) 2016-09-06
ZA201207900B (en) 2013-06-26
CA2794042A1 (fr) 2011-09-29
KR20130012067A (ko) 2013-01-31
EP2549988A1 (fr) 2013-01-30
AU2011231645A1 (en) 2012-10-18
RU2560693C2 (ru) 2015-08-20

Similar Documents

Publication Publication Date Title
EP2549988A1 (fr) Systèmes d'administration de médicaments à dissolution rapide
US20110237563A1 (en) Fast dissolving drug delivery systems
US20240066024A1 (en) Transmucosal delivery device with enhanced uptake
US20240108615A1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
KR20110097801A (ko) 구강 삽입용 투여 제형
EP2377526A1 (fr) Systèmes d'administration de médicaments à dissolution rapide
JP2010100550A (ja) 医薬組成物
NZ622610B2 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180023008.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11709445

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011231645

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2794042

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011709445

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127026904

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011231645

Country of ref document: AU

Date of ref document: 20110323

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012144848

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012024092

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012024092

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120924